Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:
a. Abatacept [Orencia]
b. Adalimumab [Humira]
c. Adalimumab Biosimilars
d. Apremilast [Otezla]
e. Baricitinib [Olumiant]
f. Certolizumab [Cimzia]
g. Etanercept [Enbrel]
h. Etanercept Biosimilars
i. Filgotinib [Jyseleca]
j. Golimumab [Simponi]
k. Guselkumab [Tremfya]
l. Infliximab [Remicade]
m. Infliximab Biosimilars
n. Ixekizumab [Taltz]
o. Risankizumab [Skyrizi]
p. Rituximab [MabThera]
q. Rituximab Biosimilars
r. Sarilumab [Kevzara]
s. Secukinumab [Cosentyx]
t. Tocilizumab [Ro Actemra]
u. Tofacitinib [Xeljanz]
v. Upadacitinib [Rinvoq]
w. Ustekinumab [Stelara]
Q2. Could you please provide the numbers of patients treated for Psoriatic Arthritis ONLY in the last 3 months with the following drugs.
a. Abatacept [Orencia]
b. Adalimumab [Humira]
c. Adalimumab Biosimilars
d. Apremilast [Otezla]
e. Certolizumab [Cimzia]
f. Etanercept [Enbrel]
g. Etanercept Biosimilars
h. Golimumab [Simponi]
i. Guselkumab [Tremfya]
j. Infliximab [Remicade]
k. Infliximab Biosimilars
l. Ixekizumab [Taltz]
m. Risankizumab [Skyrizi]
n. Secukinumab [Cosentyx]
o. Tofacitinib [Xeljanz]
p. Upadacitinib [Rinvoq]
q. Ustekinumab [Stelara]

Download response Biologic and biosimilar products within Rheumatology. 081021.docx